HAG
CRSP icon

HighPoint Advisor Group’s CRISPR Therapeutics CRSP Stock Holding History

HighPoint Advisor Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,761
Closed -$302K – 741
2025
Q4 		$302K Buy
5,761
+793
+16% +$47.5K 0.01% 848
2025
Q3 		$322K Sell
4,968
-295
-6% -$16.9K 0.02% 511
2025
Q2 		$256K Buy
+5,263
New +$204K 0.01% 569
2025
Q1 		– Sell
-5,091
Closed -$202K – 672
2024
Q4 		$202K Buy
5,091
+92
+2% +$4.34K 0.01% 635
2024
Q3 		$254K Buy
4,999
+438
+10% +$22.2K 0.01% 550
2024
Q2 		$257K Sell
4,561
-14
-0.3% -$810 0.02% 517
2024
Q1 		$255K Buy
4,575
+261
+6% +$18.7K 0.02% 510
2023
Q4 		$307K Buy
+4,314
New +$238K 0.02% 466
2022
Q2 		$278K Buy
+3,826
New +$225K 0.03% 408
2021
Q3 		$922K Buy
8,239
+237
+3% +$29.8K 0.09% 187
2021
Q2 		$1.29M Sell
8,002
-143
-2% -$17.4K 0.13% 132
2021
Q1 		$943K Buy
8,145
+2,007
+33% +$303K 0.11% 152
2020
Q4 		$1.03M Buy
6,138
+248
+4% +$29.3K 0.13% 139
2020
Q3 		$609K Buy
5,890
+590
+11% +$52.3K 0.11% 154
2020
Q2 		$416K Buy
5,300
+150
+3% +$8.77K 0.09% 190
2020
Q1 		$278K Buy
+5,150
New +$266K 0.07% 224
2019
Q4 		– Sell
-3,400
Closed -$171K – 393
2019
Q3 		$171K Buy
3,400
+750
+28% +$35.8K 0.04% 339
2019
Q2 		$130K Buy
+2,650
New +$106K 0.03% 392

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HighPoint Advisor Group's CRSP Position: Q1 2026 in Review

HighPoint Advisor Group sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 5,761 shares — an estimated $302K sold.

HighPoint Advisor Group first reported a position in CRSP in Q2 2019 and held it in 18 quarters. The position peaked at $1.29M in Q2 2021. 491 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • HighPoint Advisor Group reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HighPoint Advisor Group sold 5,761 CRISPR Therapeutics shares in Q1 2026, an estimated $302K.
  • HighPoint Advisor Group first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 18 quarters.
  • HighPoint Advisor Group's CRISPR Therapeutics position peaked at $1.29M in Q2 2021.
  • 491 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.